Table 2.
Comorbidities, therapy, and vaccinations
| Total N = 522 | Op N = 353 | C N = 169 | P value | ||||
|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | ||
| Comorbidities | |||||||
| COPD | 35 | 6.7 | 21 | 5.9 | 14 | 8.3 | 0.318 |
| OSAS | 105 | 20.1 | 57 | 16.1 | 48 | 28.4 | 0.001 |
| B-PAP/C-PAP | 35 | 6.7 | 23 | 6.5 | 12 | 7.1 | 0.803 |
| Hypertension | 166 | 31.8 | 97 | 27.5 | 69 | 40.8 | 0.002 |
| Diabetes/oral hypoglycemic | 62 | 11.9 | 34 | 9.6 | 28 | 16.6 | 0.022 |
| Diabetes/insulin | 11 | 2.1 | 1 | 0.3 | 10 | 5.9 | <0.001 |
| Hypertriglyceridemia | 64 | 12.3 | 32 | 9.1 | 32 | 18.9 | 0.001 |
| Hypercholesterolemia | 127 | 24.3 | 71 | 20.1 | 56 | 33.1 | 0.001 |
| Smoking | 147 | 28.2 | 96 | 27.2 | 51 | 30.2 | 0.478 |
| Surgery (non-bariatric) | 376 | 72.0 | 243 | 68.8 | 133 | 78.7 | 0.019 |
| Previous pneumonia | 57 | 10.9 | 34 | 9.6 | 23 | 13.6 | 0.173 |
| Autoimmune diseases | 39 | 7.5 | 23 | 6.5 | 16 | 9.5 | 0.230 |
| Malignancies | 30 | 5.7 | 20 | 5.7 | 10 | 5.9 | 0.908 |
| Immune deficiencies | 15 | 2.9 | 9 | 2.5 | 6 | 3.6 | 0.522 |
| Therapy | |||||||
| ACE-inhibitors | 75 | 14.4 | 44 | 12.5 | 31 | 18.3 | 0.073 |
| Colchicine | 2 | 0.4 | 1 | 0.3 | 1 | 0.6 | 0.594 |
| Hydroxychloroquine | 2 | 0.4 | 1 | 0.3 | 1 | 0.6 | 0.594 |
| Steroids | 19 | 3.6 | 14 | 4.0 | 5 | 3.0 | 0.565 |
| Vaccine | |||||||
| Seasonal Flu, 2019–2020 | 119 | 22.8 | 77 | 21.8 | 42 | 24.9 | 0.439 |
| Seasonal Flu, any | 170 | 32.6 | 116 | 32.9 | 54 | 32.0 | 0.836 |
| BCG | 78 | 14.9 | 57 | 16.1 | 21 | 12.4 | 0.264 |
| Pneumonia, any | 44 | 8.4 | 28 | 7.9 | 16 | 9.5 | 0.555 |
Op Operated patients; C Candidates for surgery; COPD Chronic Obstructive Pulmonary Disease; OSAS Obstructive Sleep Apnea Syndrome; BCG Bacillus Calmette–Guérin